The most widely used DPP4 inhibitors include sitagliptin, linagliptin, saxagliptin, alogliptin, vildagliptin, anagliptin, gemigliptin, and teneligliptin; these are implemented into the treatment algorithms of T2DM in many national and international guidelines [8,37]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.